Article
Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.
HIV clinical trials - 1 Feb 2016
Porter Danielle P, Toma Jonathan, Tan Yuping, Solberg Owen, Cai Suqin, Kulkarni Rima, Andreatta Kristen, Lie Yolanda, Chuck Susan K, Palella Frank, Miller Michael D, White Kirsten L
Abstract excerpt
OBJECTIVES: Antiretroviral regimen switching may be considered for HIV-1-infected, virologically-suppressed patients to enable treatment simplification or improve tolerability, but should be guided by knowledge of pre-existing drug resistance. The current study examined the impact of pre-existing drug resistance mutations on virologic outcomes among virologically-suppressed patients switching to Rilpivirine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.